Formic Acid

Formic Acid

SCHEMBL4665793

Cc1ccc(S(=O)(=O)Nc2ccc(Nc3cc(-c4ccc5c(cnn5CCN(C)C)c4)ncn3)cc2)cc1.O=CO

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 2/20 0.40
JAK3 P52333 2/20 0.40
JAK2 O60674 1/20 0.40
PIM1 P11309 1/20 0.39
EGFR P00533 4/20 0.38
KIT P10721 6/20 0.38
HTR6 P50406 1/20 0.37
GSK3B P49841 1/20 0.37
BACE1 P56817 1/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
PIP4K2A P48426 1/20 0.35
PIP4K2B P78356 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGAV P06756 1/20 0.35
ITGA2B P08514 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL4667433 0.89 JAK1 (0.38) JAK1JAK3JAK2EGFRKIT
Formic Acid SCHEMBL4663826 0.87 JAK1 (0.42) JAK1JAK3JAK2EGFRKDM4E
Formic Acid SCHEMBL4663834 0.86 JAK1 (0.40) JAK1JAK3JAK2EGFRHTR6
SCHEMBL4665797 0.84 EGFR (0.38) JAK1JAK3JAK2EGFRBACE1
SCHEMBL4665655 0.83 HTR6 (0.53) EGFRHTR6KDM4EGAAMAPT
SCHEMBL4663894 0.80 BPTF (0.52) PIM1EGFRHTR6KDM4EGAA
Formic Acid SCHEMBL4667457 0.80 HTR6 (0.51) EGFRKITHTR6KDM4EGAA
Formic Acid SCHEMBL4666208 0.79 HTR6 (0.46) EGFRHTR6KDM4EGAAMAPT
SCHEMBL4667434 0.78 MAPK1 (0.37) JAK1JAK3JAK2EGFRBACE1
Formic Acid SCHEMBL4667472 0.77 PAX8 (0.44) KITHTR6GSK3BKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 JAK1 47/4885JAK3 79/4885JAK2 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.